Dimensional Fund Advisors LP Trims Position in Haemonetics Co. (HAE)

Share on StockTwits

Dimensional Fund Advisors LP lessened its position in Haemonetics Co. (NYSE:HAE) by 7.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 1,440,600 shares of the medical instruments supplier’s stock after selling 111,369 shares during the period. Dimensional Fund Advisors LP’s holdings in Haemonetics were worth $129,193,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Columbus Circle Investors lifted its position in shares of Haemonetics by 30.8% in the 2nd quarter. Columbus Circle Investors now owns 260,678 shares of the medical instruments supplier’s stock valued at $23,378,000 after acquiring an additional 61,375 shares in the last quarter. Swiss National Bank lifted its position in shares of Haemonetics by 2.2% in the 1st quarter. Swiss National Bank now owns 91,600 shares of the medical instruments supplier’s stock valued at $6,701,000 after acquiring an additional 2,000 shares in the last quarter. Amalgamated Bank lifted its position in shares of Haemonetics by 13.6% in the 2nd quarter. Amalgamated Bank now owns 8,757 shares of the medical instruments supplier’s stock valued at $785,000 after acquiring an additional 1,046 shares in the last quarter. Chicago Equity Partners LLC lifted its position in shares of Haemonetics by 34.0% in the 2nd quarter. Chicago Equity Partners LLC now owns 86,665 shares of the medical instruments supplier’s stock valued at $7,772,000 after acquiring an additional 22,000 shares in the last quarter. Finally, OppenheimerFunds Inc. lifted its position in shares of Haemonetics by 1,584.7% in the 1st quarter. OppenheimerFunds Inc. now owns 197,852 shares of the medical instruments supplier’s stock valued at $14,475,000 after acquiring an additional 186,108 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

In other Haemonetics news, CEO Christopher Simon sold 5,139 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $89.31, for a total value of $458,964.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William P. Mr. Burke sold 841 shares of the stock in a transaction that occurred on Thursday, October 25th. The stock was sold at an average price of $46.76, for a total transaction of $39,325.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,880 shares of company stock valued at $1,284,307. Insiders own 1.04% of the company’s stock.

HAE stock opened at $111.11 on Thursday. Haemonetics Co. has a 12-month low of $41.54 and a 12-month high of $112.82. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.84 and a quick ratio of 1.94. The company has a market capitalization of $5.77 billion, a price-to-earnings ratio of 59.42, a P/E/G ratio of 4.59 and a beta of 1.00.

Haemonetics (NYSE:HAE) last released its earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.17. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. The company had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. research analysts expect that Haemonetics Co. will post 2.28 earnings per share for the current fiscal year.

HAE has been the subject of several research analyst reports. Jefferies Financial Group upped their price target on shares of Haemonetics from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, June 14th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a research report on Tuesday, June 12th. Morgan Stanley upped their price target on shares of Haemonetics from $77.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, May 9th. Barrington Research upped their price target on shares of Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a research report on Thursday, August 9th. Finally, TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $98.33.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply